Adicet Bio Appoints Lloyd Klickstein, MD, Ph.D. to Board of Directors Page 1

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, MD, Ph.D. to its Board of Directors.

“We are pleased to welcome Dr. Klickstein to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Dr. Klickstein’s expertise in rheumatology and immunology, proven track record in drug development, and scientific knowledge of our gamma-delta T-cell platform as a former executive at Adicet will be extremely valuable as we advance our autoimmune programs across multiple indications. I look forward to working with Lloyd and his contributions to our Board of Directors and pipeline of differentiated gamma-delta CAR T therapies.”